Evidence map›Paper›PMID 27230668›Full record

ArticleBMC endocrine disorders2016

Predictive value of serum testosterone for type 2 diabetes risk assessment in men.

Evan Atlantis, Paul Fahey, Sean Martin, Peter O'Loughlin, Anne W Taylor, Robert J Adams, Zumin Shi, Gary Wittert

Open access · goldAbstract read
In one paragraph

Article in BMC endocrine disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Obesity, type 2 diabetes, and testosterone in ageing men.Reviews in endocrine & metabolic disorders · 2022
    Review
  12. The Role of Testosterone in the Elderly: What Do We Know?International journal of molecular sciences · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Evan AtlantisSchool of Nursing and Midwifery, Western Sydney University, Sydney, NSW, Australia. e.atlantis@westernsydney.edu.au.
Paul FaheySchool of Science and Health, Western Sydney University, Sydney, NSW, Australia.
Sean MartinSchool of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Peter O'LoughlinChemical Pathology, SA Pathology, Adelaide, South Australia, Australia.
Anne W TaylorPopulation Research and Outcome Studies, University of Adelaide, Adelaide, South Australia, Australia.
Robert J AdamsSchool of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Zumin ShiPopulation Research and Outcome Studies, University of Adelaide, Adelaide, South Australia, Australia.
Gary WittertSchool of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
University of Adelaide · AUWestern Sydney University · AUSouth Australia Pathology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEffective prevention of type 2 diabetes (T2D) requires early identification of high-risk individuals who might benefit from intervention. We sought to determine whether low serum testosterone, a novel risk factor for T2D in men, adds clinically meaningful information beyond current T2D risk models.

methodsThe Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) study population consists of 2563 community-dwelling men aged 35-80 years in Adelaide, Australia. Of the MAILES participants, 2038 (80.0 %) provided information at baseline (2002-2006) and follow-up (2007-2010). After excluding participants with diabetes (n = 317), underweight (n = 5), and unknown BMI status (n = 11) at baseline; and unknown diabetes status (n = 50) at follow-up; 1655 participants were followed for 5 years. T2D at baseline and follow-up was defined by self-reported diabetes, or fasting plasma glucose (FPG) ≥7.0 mmol/L (126.1 mg/dL), or glycated haemoglobin (HbA1c) ≥6.5 %, or diabetes medications. Risk models were tested using logistic regression models. Sensitivity, specificity, positive predictive values (PPV) were used to identify the optimal cut-off point for low serum testosterone for incident T2D and the area under the receiver operating characteristic (AROC) curve was used to summarise the predictive power of the model. 15.5 % of men had at least one missing predictor variable; addressed through multiple imputation.

resultsThe incidence rate of T2D was 8.9 % (147/1655) over a median follow-up of 4.95 years (interquartile range: 4.35-5.00). Serum testosterone level predicted incident T2D (relative risk 0.96 [95 % CI: 0.92,1.00], P = 0.032) independent of current risk models including the AUSDRISK, but did not improve corresponding AROC statistics. A cut-off point of <16 nmol/L for low serum testosterone, which classified about 43 % of men, returned equal sensitivity (61.3 % [95 % CI: 52.6,69.4]) and specificity (58.3 % [95 % CI: 55.6,60.9) for predicting T2D risk, with a PPV of 12.9 % (95 % CI: 10.4,15.8).

conclusionsLow serum testosterone predicts an increased risk of developing T2D in men over 5 years independent of current T2D risk models applicable for use in routine clinical practice. Screening for low serum testosterone in addition to risk factors from current T2D risk assessment models or tools, including the AUSDRISK, would identify a large subgroup of distinct men who might benefit from targeted preventive interventions.

Indexed as

AdultAgedAged, 80 and overAustraliaBlood GlucoseCohort StudiesDiabetes Mellitus, Type 2Early DiagnosisHumansIncidenceMaleMiddle AgedPredictive Value of TestsPrognosisRisk AssessmentRisk FactorsBlood GlucoseTestosteroneCohortDiabetesIncidencePrognosisROCScreeningTestosterone

Identifiers

PMID27230668
PMCPMC4882776
OpenAlexW2395663401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.